Background and Aims: Immune checkpoint inhibitors (ICIs) exhibit significant clinical activity in patients with advanced hepatocellular carcinoma (HCC). This study explored whether tumor response to ICIs in HCC varies among different organs. Methods: We reviewed the data of patients with advanced HCC who had received ICIs. Patients with measurable diseases were enrolled. Organ-specific response criteria, adapted from RECIST 1.1 and immune-related RECIST, were used to evaluate the objective response to ICIs in tumors located in the liver, lung, lymph node, and other intra-abdominal sites. Results: Of the 75 enrolled patients with advanced HCC, 51 and 11 patients had chronic hepatitis B virus and chronic hepatitis C virus infection, respectively. Regarding ICI treatment, 58, 1, and 16 patients had undergone anti-PD-1/anti-PD-L1 monoclonal antibody (mAb) alone, anti-CTLA4 mAb alone, and anti-PD-1 mAb plus anti-CTLA4 mAb, respectively; 20 and 55 patients had received ICIs as first-line or ≥second-line therapy. The overall objective response rate (ORR) was 28.0%. In total, 58, 34, 19, and 18 patients had measurable hepatic tumors and lung, lymph node, and other intra-abdominal metastases, and the corresponding organ-specific ORRs were 22.4, 41.2, 26.3, and 38.9%, respectively. Of the 39 patients who had both hepatic and extrahepatic tumors, 12 had disease control in extrahepatic tumors while progressive disease (PD) in hepatic tumors, whereas only 4 exhibited disease control in hepatic tumors while PD in extrahepatic tumors (p = 0.046, McNemar test). Of the 16 patients with only evaluable tumors in the liver and lungs at baseline, 8 had disease control in the lungs while PD in the liver, and none experienced disease control in the liver while PD in the lungs (p = 0.005). Conclusions: The hepatic tumors of HCC may be less responsive to ICIs than extrahepatic lesions. Lung metastases responded most favorably to ICIs. The mechanisms underlying this differential response to ICIs warrant further investigation.

1.
Llovet
JM
,
Ricci
S
,
Mazzaferro
V
,
Hilgard
P
,
Gane
E
,
Blanc
JF
, et al.;
SHARP Investigators Study Group
.
Sorafenib in advanced hepatocellular carcinoma
.
N Engl J Med
.
2008
Jul
;
359
(
4
):
378
90
.
[PubMed]
0028-4793
2.
Cheng
AL
,
Kang
YK
,
Chen
Z
,
Tsao
CJ
,
Qin
S
,
Kim
JS
, et al.
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
.
Lancet Oncol
.
2009
Jan
;
10
(
1
):
25
34
.
[PubMed]
1470-2045
3.
Bruix
J
,
Qin
S
,
Merle
P
,
Granito
A
,
Huang
YH
,
Bodoky
G
, et al.;
RESORCE Investigators
.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
.
Lancet
.
2017
Jan
;
389
(
10064
):
56
66
.
[PubMed]
0140-6736
4.
Kudo
M
,
Finn
RS
,
Qin
S
,
Han
KH
,
Ikeda
K
,
Piscaglia
F
, et al.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
.
Lancet
.
2018
Mar
;
391
(
10126
):
1163
73
.
[PubMed]
0140-6736
5.
Abou-Alfa
GK
,
Meyer
T
,
Cheng
AL
,
El-Khoueiry
AB
,
Rimassa
L
,
Ryoo
BY
, et al.
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
.
N Engl J Med
.
2018
Jul
;
379
(
1
):
54
63
.
[PubMed]
0028-4793
6.
Sangro
B
,
Gomez-Martin
C
,
de la Mata
M
,
Iñarrairaegui
M
,
Garralda
E
,
Barrera
P
, et al.
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
.
J Hepatol
.
2013
Jul
;
59
(
1
):
81
8
.
[PubMed]
0168-8278
7.
El-Khoueiry
AB
,
Sangro
B
,
Yau
T
,
Crocenzi
TS
,
Kudo
M
,
Hsu
C
, et al.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
.
Lancet
.
2017
Jun
;
389
(
10088
):
2492
502
.
[PubMed]
0140-6736
8.
Zhu
AX
,
Finn
RS
,
Edeline
J
,
Cattan
S
,
Ogasawara
S
,
Palmer
D
, et al.;
KEYNOTE-224 investigators
.
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
.
Lancet Oncol
.
2018
Jul
;
19
(
7
):
940
52
.
[PubMed]
1470-2045
9.
van Kessel
CS
,
Samim
M
,
Koopman
M
,
van den Bosch
MA
,
Borel Rinkes
IH
,
Punt
CJ
, et al.
Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases
.
Eur J Cancer
.
2013
Jul
;
49
(
11
):
2486
93
.
[PubMed]
0959-8049
10.
Chen
ZY
,
Zhong
WZ
,
Zhang
XC
,
Su
J
,
Yang
XN
,
Chen
ZH
, et al.
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas
.
Oncologist
.
2012
;
17
(
7
):
978
85
.
[PubMed]
1083-7159
11.
Mete
UK
,
Singh
DV
,
Kakkar
N
.
Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: is this an anti-angiogenic potentiation of cancer?
Urol Ann
.
2015
Jul-Sep
;
7
(
3
):
387
90
.
[PubMed]
0974-7796
12.
Goasguen
N
,
de Chaisemartin
C
,
Brouquet
A
,
Julié
C
,
Prevost
GP
,
Laurent-Puig
P
, et al.
Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents
.
Int J Cancer
.
2010
Sep
;
127
(
5
):
1028
37
.
[PubMed]
0020-7136
13.
Schmid
K
,
Oehl
N
,
Wrba
F
,
Pirker
R
,
Pirker
C
,
Filipits
M
.
EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases
.
Clin Cancer Res
.
2009
Jul
;
15
(
14
):
4554
60
.
[PubMed]
1078-0432
14.
Abdi
EA
,
Petrik
P
.
An unusual case of renal cancer showing mixed tumor response to interferon
.
Am J Med
.
1987
Dec
;
83
(
6
):
1147
50
.
[PubMed]
0002-9343
15.
Lindsey
KR
,
Gritz
L
,
Sherry
R
,
Abati
A
,
Fetsch
PA
,
Goldfeder
LC
, et al.
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma
.
Clin Cancer Res
.
2006
Apr
;
12
(
8
):
2526
37
.
[PubMed]
1078-0432
16.
Carrasco
J
,
Van Pel
A
,
Neyns
B
,
Lethé
B
,
Brasseur
F
,
Renkvist
N
, et al.
Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells
.
J Immunol
.
2008
Mar
;
180
(
5
):
3585
93
.
[PubMed]
0022-1767
17.
Bol
KF
,
Figdor
CG
,
Aarntzen
EH
,
Welzen
ME
,
van Rossum
MM
,
Blokx
WA
, et al.
Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients
.
OncoImmunology
.
2015
Apr
;
4
(
8
):
e1019197
.
[PubMed]
2162-4011
18.
Koelzer
VH
,
Rothschild
SI
,
Zihler
D
,
Wicki
A
,
Willi
B
,
Willi
N
, et al.
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study
.
J Immunother Cancer
.
2016
Mar
;
4
(
1
):
13
.
[PubMed]
2051-1426
19.
Eisenhauer
EA
,
Therasse
P
,
Bogaerts
J
,
Schwartz
LH
,
Sargent
D
,
Ford
R
, et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
.
Eur J Cancer
.
2009
Jan
;
45
(
2
):
228
47
.
[PubMed]
0959-8049
20.
Nishino
M
,
Giobbie-Hurder
A
,
Gargano
M
,
Suda
M
,
Ramaiya
NH
,
Hodi
FS
.
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements
.
Clin Cancer Res
.
2013
Jul
;
19
(
14
):
3936
43
.
[PubMed]
1078-0432
21.
Jimenez-Sanchez
A
,
Memon
D
,
Pourpe
S
,
Veeraraghavan
H
,
Li
Y
,
Vargas
HA
,
Gill
MB
,
Park
KJ
,
Zivanovic
O
,
Konner
J
,
Ricca
J
,
Zamarin
D
,
Walther
T
,
Aghajanian
C
,
Wolchok
JD
,
Sala
E
,
Merghoub
T
,
Snyder
A
,
Miller
ML
:
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.
Cell
2017
;170:927-938 e20.
22.
Ascierto
ML
,
Makohon-Moore
A
,
Lipson
EJ
,
Taube
JM
,
McMiller
TL
,
Berger
AE
, et al.
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy
.
Clin Cancer Res
.
2017
Jun
;
23
(
12
):
3168
80
.
[PubMed]
1078-0432
23.
Remark
R
,
Alifano
M
,
Cremer
I
,
Lupo
A
,
Dieu-Nosjean
MC
,
Riquet
M
, et al.
Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin
.
Clin Cancer Res
.
2013
Aug
;
19
(
15
):
4079
91
.
[PubMed]
1078-0432
24.
Baine
MK
,
Turcu
G
,
Zito
CR
,
Adeniran
AJ
,
Camp
RL
,
Chen
L
, et al.
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
.
Oncotarget
.
2015
Sep
;
6
(
28
):
24990
5002
.
[PubMed]
1949-2553
25.
Müller
P
,
Rothschild
SI
,
Arnold
W
,
Hirschmann
P
,
Horvath
L
,
Bubendorf
L
, et al.
Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells
.
Cancer Immunol Immunother
.
2016
Jan
;
65
(
1
):
1
11
.
[PubMed]
0340-7004
26.
Lu
LC
,
Lee
YH
,
Chang
CJ
,
Shun
CT
,
Fang
CY
,
Shao
YY
, et al.
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
.
Liver Cancer
.
2019
Mar
;
8
(
2
):
110
20
.
[PubMed]
2235-1795
27.
Khoja
L
,
Kibiro
M
,
Metser
U
,
Gedye
C
,
Hogg
D
,
Butler
MO
, et al.
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
.
Br J Cancer
.
2016
Nov
;
115
(
10
):
1186
92
.
[PubMed]
0007-0920
28.
Tumeh
PC
,
Hellmann
MD
,
Hamid
O
,
Tsai
KK
,
Loo
KL
,
Gubens
MA
, et al.
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
.
Cancer Immunol Res
.
2017
May
;
5
(
5
):
417
24
.
[PubMed]
2326-6066
29.
Chan
T
,
Wiltrout
RH
,
Weiss
JM
.
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments
.
Int Immunopharmacol
.
2011
Jul
;
11
(
7
):
879
89
.
[PubMed]
1567-5769
30.
Tiegs
G
,
Lohse
AW
.
Immune tolerance: what is unique about the liver
.
J Autoimmun
.
2010
Feb
;
34
(
1
):
1
6
.
[PubMed]
0896-8411
31.
You
Q
,
Cheng
L
,
Kedl
RM
,
Ju
C
.
Mechanism of T cell tolerance induction by murine hepatic Kupffer cells
.
Hepatology
.
2008
Sep
;
48
(
3
):
978
90
.
[PubMed]
0270-9139
32.
Wu
K
,
Kryczek
I
,
Chen
L
,
Zou
W
,
Welling
TH
.
Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions
.
Cancer Res
.
2009
Oct
;
69
(
20
):
8067
75
.
[PubMed]
0008-5472
33.
Ikeda
M
,
Okusaka
T
,
Ueno
H
,
Morizane
C
,
Kojima
Y
,
Iwasa
S
, et al.
Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma
.
Jpn J Clin Oncol
.
2008
Oct
;
38
(
10
):
675
82
.
[PubMed]
0368-2811
34.
Chang
CJ
,
Yang
YH
,
Chiu
CJ
,
Lu
LC
,
Liao
CC
,
Liang
CW
, et al.
Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma
.
Int J Cancer
.
2018
May
;
142
(
9
):
1878
89
.
[PubMed]
0020-7136
35.
Huang
AC
,
Postow
MA
,
Orlowski
RJ
,
Mick
R
,
Bengsch
B
,
Manne
S
, et al.
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
.
Nature
.
2017
May
;
545
(
7652
):
60
5
.
[PubMed]
0028-0836
36.
Joseph
RW
,
Elassaiss-Schaap
J
,
Kefford
R
,
Hwu
WJ
,
Wolchok
JD
,
Joshua
AM
, et al.
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
.
Clin Cancer Res
.
2018
Oct
;
24
(
20
):
4960
7
.
[PubMed]
1078-0432
37.
Patel
MR
,
Ellerton
J
,
Infante
JR
,
Agrawal
M
,
Gordon
M
,
Aljumaily
R
, et al.
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
.
Lancet Oncol
.
2018
Jan
;
19
(
1
):
51
64
.
[PubMed]
1470-2045
38.
Lencioni
R
,
Llovet
JM
.
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
.
Semin Liver Dis
.
2010
Feb
;
30
(
1
):
52
60
.
[PubMed]
0272-8087
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.